License and Collaboration Arrangements (Additional Information) (Details) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)
Zai Lab | Research and Development Support
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future potential milestone payment receivable	$ 91,000	$ 91,000
License revenue recognized	3	3
PAION AG
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future potential milestone payment receivable	109,500	109,500
Everest Medicines Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales milestone payments receivable	20,000	20,000
License revenue recognized		$ 8,000
Royalties payable period after first commercial sale of product		10 years
Deferred revenue	500	$ 500
Everest Medicines Limited | Commercial Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of reimbursed for direct and certain indirect manufacturing costs		110.00%
Deferred revenue	$ 2,800	$ 2,800
George Washington University
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payable on net sales		6.00%
Percentage of royalty on payments received from sublicensees		15.00%
Harvard University
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payable on net sales		5.00%
Percentage of royalty on payments received from sublicensees		20.00%
Cost of license revenue		$ 1,600
Clinical development and regulatory milestones amount payable		$ 15,100
Percentage of minimum royalty rate		4.50%
Percentage of maximum royalty based on achievement of annual net product sales thresholds		7.50%
Paratek Pharmaceuticals, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payable on net sales		2.25%
Claim expiration		2023-10